Dr. Partha Das, MBBS, MD

Pathologist with a morbid interest in #data #AI & #ML. BM driven drug development #PrecisionMedicine Leader @Janssen. #MolPath #precisiononcology. T/RT my own

[Dr. Partha Das, MBBS, MD @pdmanas30]

⁦@theAGU⁩ Interested in how geysers function and their academic value as volcano analogs? Join @ucdavis student Uthkarsh Das for an interesting talk on a novel theoretical model and laboratory validation of fluid motion in bubble trap geysers #AGU22 https://t.co/x4uaTA5ldF

[Dr. Partha Das, MBBS, MD @pdmanas30]

✅ Just wrapped #CAP25 in Orlando — key takeaways:
•AI is moving from pilot to practice, with CAP + CHAI setting standards
•New research in molecular, renal, GI, & pulmonary pathology refining workflows & practice

Pathology’s future = human expertise + AI innovation.

[Dr. Partha Das, MBBS, MD @pdmanas30]

#CAP25

Heading to Orlando for #CAP2025 — looking forward to insights on pathology innovations, precision medicine, and quality assurance. Excited to see how #AI is shaping diagnostics and the future of our labs.

[Dr. Partha Das, MBBS, MD @pdmanas30]

@pashtoonkasi Congratulations 🎊

[Dr. Partha Das, MBBS, MD @pdmanas30]

@EytanRuppin Brilliant article. Very comprehensive and informative. Thank you for the article Dr. Ruppin.

[Dr. Partha Das, MBBS, MD @pdmanas30]

#mycompany

[J&J Innovative Medicine @JNJInnovMed]

Today, the U.S. FDA approved our targeted therapy in combination with chemotherapy as a first-line treatment for patients living with locally advanced or metastatic non-small cell #LungCancer with EGFR exon 20 insertion mutations: https://t.co/R1YI94raAA

[Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD]

Please take a minute to fill out the survey on #BiomarkerTesting. This will help understand the gaps, and define our efforts moving forward globally, to personalize therapy in #NSCLC @IASLC @karenkellymd @MattSmeltzer

https://t.co/CV1RyvWVhX

[J&J Innovative Medicine @JNJInnovMed]

The U.S. FDA has granted full approval for our targeted therapy for patients with genetically defined, locally advanced, or metastatic urothelial carcinoma. Learn about our commitment to advancing the treatment of #BladderCancer: https://t.co/js32AK52SQ

[Mark Wildgust (he/him) @MAWildgust]

@JNJInnovation has successfully submitted the MARIPOSA Phase 3 study to the FDA. 52 days since #DrCho presented these results at #ESMO2023. #NSCLC #MyCompany

https://t.co/kNj4FjzqAO

[Dr. Partha Das, MBBS, MD @pdmanas30]

@venkytalks Nice to see the ‘gang’ again. Looking great all of you.

[Dr. Partha Das, MBBS, MD @pdmanas30]

@ns_chd @ADesaiMD @SewantiLimaye @IASLC @StephenVLiu @NarjustFlorezMD @OncoAlert @LungCancerRx @DrSanjayPopat @VivekSubbiah @neerajaiims @CharuAggarwalMD @JackWestMD @RamalingamMD @ShirishGadgeel @esinghimd @PatelOncology @jillfeldman4 Great initiative. Looking forward to listening. I am sure you will include biomarker testing in the discussion.

[Dr. Partha Das, MBBS, MD @pdmanas30]

#mycompany

[J&J Innovative Medicine @JNJInnovMed]

#NEWS: We announced topline results from the Phase 3 MARIPOSA study in patients with EGFR-mutated non-small cell lung cancer, an important step forward in our aim to advance treatment options for patients. https://t.co/9Yc75w4wTg #LungCancer #NSCLC

[Dr. Partha Das, MBBS, MD @pdmanas30]

@Sinchita_Roy @NIHClinicalCntr @MSKCancerCenter @MDAndersonNews @TimAllenMDJD @NayarRitu @bfaquin @vgprieto14 @NCIKenAldape @Hememachine @GenieLandon @mdlozanoe @PVielh @eva_wojcik Congratulations Sinchita. Well deserved.

[Dr. Partha Das, MBBS, MD @pdmanas30]

@NitinJainMD @MDAndersonNews @DrHKantarjian @mkonople @GCC_Cortes @wwierda @mpdrc @Phari @myelomaMD @BldCancerDoc @doctorpemm Congratulations Nitin. Very proud of your achievement as a fellow AIIMSONIAN and MDACC Alumnus.

[IASLC @IASLC]

The @IASLC Corporate Roundtable met on 6/2/23 in Chicago, IL, to address barriers to access biomarker testing for advanced #NSCLC in diverse health care systems worldwide, focusing on the crucial need to increase testing for #lungcancer globally. #LCSM #ASCO23

[Dr. Partha Das, MBBS, MD @pdmanas30]

Do you remember when you joined Twitter? I do! #MyTwitterAnniversary

[Dr. Partha Das, MBBS, MD @pdmanas30]

#MyCompany

[J&J Innovative Medicine @JNJInnovMed]

UPDATE: Our submission to the U.S. FDA for a new targeted therapy for patients with BRCA-positive metastatic castration-resistant #ProstateCancer #mCRPC has received Priority Review. https://t.co/56gMkdGWQI

[Dr. Partha Das, MBBS, MD @pdmanas30]

@girlscientist X-like, yet distinct,
A clue to what makes you, you,
Guess and find your truth.

[Dr. Partha Das, MBBS, MD @pdmanas30]

#mycompany

[Dr. Partha Das, MBBS, MD @pdmanas30]

@Vik_deshpandeMD Not a surprise…. You are multitalented 😀😀